April 3, 2023 07:22 AM EDTUpdated 12:03 PM
People

Vedere Bio II, gene ther­a­py biotech born out of No­var­tis buy­out, clos­es down

Amber Tong

When No­var­tis swooped in to buy Vedere Bio and its pre­clin­i­cal gene ther­a­py for $150 mil­lion up­front in 2020, Vedere CEO Cyrus Moza­yeni …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: No­var­tis claims best earn­ings in years, val­i­dat­ing shift to pure-play strat­e­gy

Dai­ichi Sankyo taps new CEO, aims to build up ADC fran­chise

Ab­b­Vie ex­ec­u­tives bask in Skyrizi, Rin­voq suc­cess­es as the drugs take up Hu­mi­ra's man­tle

As­traZeneca scraps UK vac­cine site ex­pan­sion af­ter gov­ern­ment bud­get cuts 

Trump 2.0 blog: Trump com­mits to pres­sure on drug prices; Kennedy's nom­i­na­tion

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times